Income Statement
Quarterly Data

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Merck & Co. Inc., consolidated income statement (quarterly data)

US$ in millions

3 months ended:	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Sales	16,112)	15,775)	14,631)	15,962)	15,035)	14,487)	13,830)	14,959)	14,593)	15,901)	13,521)	13,154)	11,402)	10,627)	12,514)	12,551)	10,872)	12,057)	11,867)	12,397)	11,760)	10,816)
Cost of sales	(3,745)	(3,540)	(3,912)	(4,264)	(4,024)	(3,926)	(3,881)	(3,934)	(4,216)	(5,380)	(3,873)	(3,450)	(3,104)	(3,199)	(5,533)	(3,481)	(3,159)	(3,312)	(3,669)	(3,990)	(3,401)	(3,052)
Gross profit	12,367)	12,235)	10,719)	11,698)	11,011)	10,561)	9,949)	11,025)	10,377)	10,521)	9,648)	9,704)	8,298)	7,428)	6,981)	9,070)	7,713)	8,745)	8,198)	8,407)	8,359)	7,764)
Selling, general and administrative	(2,739)	(2,483)	(2,804)	(2,519)	(2,702)	(2,479)	(2,687)	(2,520)	(2,512)	(2,323)	(2,830)	(2,336)	(2,281)	(2,187)	(3,085)	(2,450)	(2,378)	(2,555)	(2,889)	(2,589)	(2,712)	(2,425)
Research and development	(3,500)	(3,992)	(9,627)	(3,307)	(13,321)	(4,276)	(3,775)	(4,399)	(2,798)	(2,576)	(3,067)	(2,445)	(4,321)	(2,412)	(5,836)	(3,390)	(2,123)	(2,209)	(2,548)	(3,204)	(2,189)	(1,931)
Restructuring costs	(80)	(123)	(255)	(126)	(151)	(67)	(48)	(94)	(142)	(53)	(175)	(107)	(82)	(297)	(309)	(114)	(83)	(72)	(194)	(232)	(59)	(153)
Operating income (loss)	6,048)	5,637)	(1,967)	5,746)	(5,163)	3,739)	3,439)	4,012)	4,925)	5,569)	3,576)	4,816)	1,614)	2,532)	(2,249)	3,116)	3,129)	3,909)	2,567)	2,382)	3,399)	3,255)
Other income (expense), net	(42)	33)	(79)	(126)	(172)	(89)	74)	(429)	(438)	(708)	333)	450)	103)	455)	255)	312)	390)	(71)	224)	(35)	(140)	(188)
Income (loss) from continuing operations before taxes	6,006)	5,670)	(2,046)	5,620)	(5,335)	3,650)	3,513)	3,583)	4,487)	4,861)	3,909)	5,266)	1,717)	2,987)	(1,994)	3,428)	3,519)	3,838)	2,791)	2,347)	3,259)	3,067)
Taxes on income from continuing operations	(545)	(903)	820)	(870)	(637)	(825)	(496)	(330)	(538)	(554)	(85)	(695)	(503)	(238)	(98)	(483)	(509)	(619)	(427)	(440)	(615)	(205)
Net income (loss) from continuing operations	5,461)	4,767)	(1,226)	4,750)	(5,972)	2,825)	3,017)	3,253)	3,949)	4,307)	3,824)	4,571)	1,214)	2,749)	(2,092)	2,945)	3,010)	3,219)	2,364)	1,907)	2,644)	2,862)
Income from discontinued operations, net of taxes	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	(62)	—)	332)	434)	—)	—)	—)	—)	—)	—)	—)	—)
Net income (loss)	5,461)	4,767)	(1,226)	4,750)	(5,972)	2,825)	3,017)	3,253)	3,949)	4,307)	3,762)	4,571)	1,546)	3,183)	(2,092)	2,945)	3,010)	3,219)	2,364)	1,907)	2,644)	2,862)
Net (income) loss attributable to noncontrolling interests	(6)	(5)	—)	(5)	(3)	(4)	—)	(5)	(5)	3)	(4)	(4)	(1)	(4)	(3)	(4)	(8)	—)	(7)	(6)	26)	53)
Net income (loss) attributable to Merck & Co., Inc.	5,455)	4,762)	(1,226)	4,745)	(5,975)	2,821)	3,017)	3,248)	3,944)	4,310)	3,758)	4,567)	1,545)	3,179)	(2,095)	2,941)	3,002)	3,219)	2,357)	1,901)	2,670)	2,915)

Download chart

Income statement item	Description	The company
Sales	Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.	Merck & Co. Inc. sales increased from Q4 2023 to Q1 2024 and from Q1 2024 to Q2 2024.
Operating income (loss)	The net result for the period of deducting operating expenses from operating revenues.	Merck & Co. Inc. operating income (loss) increased from Q4 2023 to Q1 2024 and from Q1 2024 to Q2 2024.
Income (loss) from continuing operations before taxes	Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.	Merck & Co. Inc. income (loss) from continuing operations before taxes increased from Q4 2023 to Q1 2024 and from Q1 2024 to Q2 2024.
Net income (loss) attributable to Merck & Co., Inc.	The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.	Merck & Co. Inc. net income (loss) attributable to Merck & Co., Inc. increased from Q4 2023 to Q1 2024 and from Q1 2024 to Q2 2024.

Merck & Co. Inc. (NYSE:MRK)

Income StatementQuarterly Data

Income Statement
Quarterly Data